Clinical Trials Logo

Clinical Trial Summary

This is a prospective,open-labelled,multi-center,randomized clinical trial.It compares the clinical efficacy and safety of there 2 drugs in the treatment of relapse active Takayasu's arteritis patients.


Clinical Trial Description

In this study, 100 relapse Takayasu's arteritis patients will be enrolled. Patients are randomized into the adalimumab treatment group and tofacitinib treatment.Patients will also be treated with reduced dose of glucocorticoid at the same time. The primary end point is the percentage of patients who are in complete response at week 12 and maintain in complete response at week 78. The efficacy will be evaluated at week 12, 24, 36, 52 and 78. If the patient does not respond to one drug at week 24, then the investigator will shift the treatment to another intervention. Safety is also monitored during the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05151848
Study type Interventional
Source Chinese SLE Treatment And Research Group
Contact Xinping Tian, MD
Phone 8613691165939
Email tianxp6@126.com
Status Recruiting
Phase Phase 4
Start date January 5, 2022
Completion date January 15, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04564001 - Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis Phase 2
Terminated NCT04882072 - A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Phase 3
Completed NCT03750929 - Aerobic Capacity and Strength Exercise in Takayasu's Arteritis N/A
Recruiting NCT04137614 - Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis N/A
Recruiting NCT02967068 - VCRC Tissue Repository
Recruiting NCT05102448 - Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis Phase 4
Recruiting NCT03893136 - The Registry Study of Takayasu Arteritis in East China
Active, not recruiting NCT00006055 - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases N/A
Completed NCT03096275 - Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis Phase 3
Recruiting NCT04299971 - Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients Phase 4
Recruiting NCT04300686 - A Pilot Study in Severe Patients With Takayasu Arteritis. Phase 4
Recruiting NCT03192878 - Infliximab Biosimilar in Takayasu's Arteritis N/A
Active, not recruiting NCT04071691 - PET Imaging of Giant Cell and Takayasu Arteritis
Recruiting NCT05904301 - Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Completed NCT02101333 - Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis Phase 3
Not yet recruiting NCT03550781 - Anti-inflammatory Treatment for Inactive Takayasu Arteritis Phase 2/Phase 3
Active, not recruiting NCT05168475 - Biologics in Refractory Vasculitis Phase 2
Completed NCT03956394 - Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging N/A
Completed NCT03430388 - Yellow Fever Vaccine in Patients With Rheumatic Diseases N/A
Completed NCT02925351 - Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases Early Phase 1